CID1231538

Cat. No.: HY-134801 CAS No.: 354126-20-8 Molecular Formula: $C_{26}H_{22}CIN_3O_3S_2$

Molecular Weight: 524.05 Target: GPR35

Pathway: GPCR/G Protein

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (95.41 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9082 mL	9.5411 mL	19.0821 mL
	5 mM	0.3816 mL	1.9082 mL	3.8164 mL
	10 mM	0.1908 mL	0.9541 mL	1.9082 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.91 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.91 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	CID1231538, a benzothiazole analogue, is a potent GPR35 antagonist (IC $_{50}$ =0.55 μ M). GPR35 is a G protein-coupled receptor (GPCR) $^{[1]}$.
In Vitro	GPR35 has gained special consideration as a result of its association with many diseases including type-2 diabetes, nociceptive pain, inflammation, mild mental retardation syndrome, metabolic disorders, and gastric cancer ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

1]. Abdalhameed MM, et al. Stru	ucture-activity relationships of benzothiazole GPR35 ar	ntagonists. Bioorg Med Chem Lett. 2017;27(3):612-615.	
	Continue Draduct has not been fully validated f	ov modical annications. For vaccovely use only	
	Caution: Product has not been fully validated f		
	Tel: 609-228-6898 Fax: 609-228-5909 Address: 1 Deer Park Dr, Suite Q, M	E-mail: tech@MedChemExpress.com onmouth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com